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The cellular prion protein PrPc is the normal counterpart of the scrapie prion protein PrPSc,
themain component of the infectious agent of transmissible spongiform encephalopathies.
The recent discovery that PrPc can serve as a receptor for the amyloid beta (Aβ) peptide and
relay its neurotoxicity is sparking renewed interest on this protein and its involvement in
signal transduction processes. Disease-associated PrPSc shares with Aβ the ability to hijack
PrPc-dependent signaling cascades, and thereby instigate pathogenic events. Among these
is an impairment of Aβ clearance, uncovered in prion-infected neuronal cells.These ﬁndings
add another facet to the intricate interplay between PrPc and Aβ. Here, we summarize the
connection between PrP-mediated signaling and Aβ clearance and discuss its pathological
implications.
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INTRODUCTION
Up to recent years, commonalities between the amyloid precursor
protein (APP) and the cellular prion protein PrPc were considered
to mainly reside in their capacity to give rise to aggregation-prone
proteins, amyloid beta (Aβ) and PrPSc (standing for scrapie iso-
form of the prion protein), both involved in neurodegenerative
disorders, Alzheimer’s disease (AD) and transmissible spongiform
encephalopathies (TSEs), respectively (Haass and Selkoe, 2007;
Aguzzi and Calella, 2009). These two diseases share neuropatho-
logical features, including synaptic damage, neuronal loss and
astrogliosis (Reiniger et al., 2011). As forAD,humanprion diseases
may have a genetic origin, while most cases are sporadic (Aguzzi
and Calella, 2009). Sporadic human prion diseases are thought
to arise from the spontaneous conformational conversion of PrPc
into its pathogenic PrPSc counterpart (Aguzzi and Calella, 2009).
PrPSc has a propensity to aggregate, form amyloid-like structures
and can act as a seed to transmit its aberrant conformation to
native PrPc molecules (Aguzzi and Calella, 2009). Such template-
directedmisfolding is also now established in the case of Aβ species
[(Jucker and Walker, 2013) for review]. Like Aβ (Langer et al.,
2011), much evidence suggests that PrPSc-associated toxicity is
imparted by small oligomers (Silveira et al., 2005). This toxicity is
assumed to be driven by the subversion of the normal function
of PrPc (Harris and True, 2006), which now also emerges as a key
event in Aβ-induced neuronal damage (Lauren et al., 2009). The
discovery that PrPc may serve as a receptor for Aβ is calling for a
better understanding of the role played by PrPc in neurons. The
relationship betweenAβ andPrPc actually extends beyond that of a
ligand-receptor connection, since the prion-induced subversion of
PrPc-dependent signaling causes impaired Aβ clearance (Pradines
et al., 2013). In this review, we summarize the recent advances
focusing on the Aβ-PrP duo and discuss the ensuing challenges.
THE BASICS OF PrPC
Understanding the interplay between Aβ and PrPc necessitates
some focus on the latter protein. PrPc is encoded by a unique
gene, Prnp, whose open reading frame is contained within a single
exon (Aguzzi and Calella, 2009). While ubiquitous, this protein is
most abundantly expressed in neurons (Linden et al., 2008). It is
located at the outer leaﬂet of the plasma membrane, to which it
is attached through a glycosyl-phosphatidylinositol (GPI) moiety.
PrPc contains two potentially glycosylated aspargine residues, at
the origin of a great diversity of isoforms (Ermonval et al., 2003).
It can also undergo three types of proteolytical cleavages. The
best studied are a so-called alpha-cleavage at position 111/112,
yielding a N-terminal N1 fragment and a C-terminal C1 frag-
ment, and a beta-cleavage in its N-terminal region giving rise to
N2 and C2 fragments [reviewed in (Checler and Vincent, 2002),
Figure 1]. The third cleavage leads to the release of a full-length
anchorless isoform of PrPc through the action of the metallo-
protease ADAM10 (Altmeppen et al., 2011; Figure 1). Of note,
similarly to APP processing, the alpha-cleavage of PrPc occurs
within a region bearing toxicity (residues 106 to 126), and may
involve the TNF-alpha converting enzyme (TACE) metallopro-
tease (Checler and Vincent, 2002), although the nature of the
proteases driving this alpha-cleavage is subject to controversy
(Altmeppen et al., 2011; Beland et al., 2012). PrPc thus exists
under a plethora of isoforms, whose distribution may vary in
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FIGURE 1 | Schematic representation of the secondary structure of PrPc.
The alpha-cleavage (green) occurs at position 111/112 and generates the N1
and C1 fragments. The beta-cleavage (orange) occurs in the vicinity of
octapeptide repeats (ORs), which bind copper ions, and generates the N2 and
C2 fragments. PrPc can also be shed from the plasma membrane through the
action of ADAM10. The protective factor STI-1 binds to PrPc at amino acids
113–128. Two main binding sites have been mapped for Aβ to the very
N-terminus (AA 23–50) and near the alpha-cleavage site at amino acids
92–110. The alpha helices (α) and beta sheets (β) are shown in purple and the
polybasic regions (+) are shown in red.
distinct brain regions, cell types or even subcellular compart-
ments and whose respective functions remain to be thoroughly
resolved (Linden et al., 2008). Clues as to PrPc normal func-
tion were greatly anticipated from the development of PrP-null
mice. However, these mice are viable, develop normally and do
not suffer from major abnormalities (Steele et al., 2007). Sub-
tle behavioral and cognitive deﬁcits were subsequently reported
in PrP-deﬁcient mice (Linden et al., 2008), in addition to an
increased vulnerability to various types of stresses (Resenberger
et al., 2011b). Noteworthy, these animals have been instrumen-
tal in substantiating the central role exerted by PrPc in the
development of prion diseases, since the knockout of the Prnp
gene confers resistance to prion infection (Bueler et al., 1993).
Further, post-infection knockdown of PrPc in neurons is sufﬁ-
cient to counteract the progression of prion neuropathogenesis
(Mallucci et al., 2003). Finally, transgenic mice expressing an
anchorless variant of PrPc (GPI-PrP) were found to efﬁciently
replicate prions upon infection, while not showing any sign of
neurodegeneration (Chesebro et al., 2005). Overall, it is now
quite well established that neuronal, GPI-anchored PrPc serves
as a relay of PrPSc-induced neuropathogenesis. On this basis,
understanding the normal function held by PrPc in neurons
appears as a necessary step to grasp how it is corrupted by
its pathogenic counterpart, PrPSc. Actually, this notion now
also applies to Aβ-related pathogenesis, as will be emphasized
below.
PrPC-DEPENDENT SIGNALING IN NEURONS: FINDINGS AND
IMPLICATIONS
The involvement of PrPc in signal transduction was initially sus-
pected from its cell surface location, as well as its enrichment
in lipid rafts (Lewis and Hooper, 2011), which allow the spa-
tial segregation of cell signaling components (Parton and del
Pozo, 2013). Using a neuronal cell line (1C11) endowed with
the capacity to differentiate into either serotonergic (1C115−HT)
or noradrenergic (1C11NE) neurons, we demonstrated that PrPc
has the capacity to trigger the activation of the Fyn kinase in
neuronal cells (Mouillet-Richard et al., 2000). This signaling cas-
cade is exclusively imparted by PrPc molecules located on the
neurites of differentiated cells and is relayed by the scaffold
protein caveolin-1 (Mouillet-Richard et al., 2000). Downstream
from Fyn, PrPc can mobilize the reactive oxygen species (ROS)
generating enzyme NADPH oxidase, and the transcription factors
ERK1/2, cAMP response element-binding protein (CREB), Egr-
1 and c-Fos (Schneider et al., 2003; Pradines et al., 2008). From
a functional point of view, the PrPc-Fyn coupling was shown
to mediate neural cell adhesion molecule (NCAM)-dependent
neurite outgrowth (Santuccione et al., 2005) and to control cal-
cium inﬂuxes in hippocampal neurons (Krebs et al., 2007). As
for NADPH oxidase-derived ROS, they can promote the catalytic
activation of TACE, subsequent TNFα shedding and bioamine
catabolism, thus exerting a neuromodulatory function (Pradines
et al., 2009). The demonstration that PrPc could serve as a recep-
tor for the chaperone protein STI-1 (Zanata et al., 2002) further set
the stage for the identiﬁcation of various cell signaling pathways
involved in neuroprotection (Chiarini et al., 2002; Lopes et al.,
2005), neurite outgrowth (Lopes et al., 2005), and/or memory
consolidation (Coitinho et al., 2007). Interestingly, the contribu-
tion of PrPc to some of these processes may involve additional
partners, such as laminin (Coitinho et al., 2006; Beraldo et al.,
2011; Santos et al., 2013). The PrPc-STI-1 interaction was also
reported to sustain neuronal protein synthesis via themTORpath-
way (Roffe et al., 2010). Finally, multiple connections have been
depicted between PrPc and neurotransmitter signaling including
crosstalk with serotonergic (Mouillet-Richard et al., 2005), nico-
tinic (Beraldo et al., 2010) and mostly glutamatergic receptors,
whether metabotropic (Beraldo et al., 2011) or ionotropic (Stys
et al., 2012). Collectively, there is now compelling evidence for
the involvement of PrPc in multiple signal transduction cascades,
whose deviation may drastically impact on neuronal function and
activity.
PATHOGENIC PRIONS DEVIATE PrPC SIGNALING
While it is now acknowledged that PrPc is mandatory for the neu-
rotoxic action of PrPSc, our current understanding of how prions
corrupt the physiological function of PrPc is still far from complete
(Harris and True, 2006). Achieving this goal is all the more chal-
lenging since PrPc encompasses a great variety of isoforms, which
may be associated with distinct partners and sustain promiscuous
functions. In addition, the repertoire of PrPc species eligible for
de novo conversion into PrPSc may vary according to the prion
strain and the cell type considered (Ermonval et al., 2003). Despite
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these hurdles, the development of in vitromodelsof prion infection
has allowed to shed some light on this issue. Taking advantage
of thecapacity of the 1C11 cell line to replicate various prion
strains (Mouillet-Richard et al., 2008), we recently reported on
the constitutive activation of signaling targets normally coupled
with PrPc in chronically infected cells (Pradines et al., 2013). In
these cells as well as in prion-infected neurospheres, prion accu-
mulation is associated with increased activities of Fyn, ERK1/2
and CREB (Figure 2). Another consequence of prion infection is
the recruitment of the stress-associated kinases p38 and JNK, as a
result of unbalanced ROS production. Downstream from CREB,
we documented that prion-infected cells exhibit a reduced activ-
ity of the matrix metalloprotease MMP-9. This observation led
us to delineate an impact on the clearance of the Aβ peptide,
as will be discussed below. Collectively, these ﬁndings support
the view that PrPSc exerts a toxic gain of PrPc function. In line
with this “gain of function” scheme, a central role of the NADPH
oxidase NOX2 subunit in prion-induced neuronal damage was
established using cerebellar organotypic culture slices (Falsig et al.,
2012). Notwithstanding, some PrPc functions may conversely be
disrupted within an infected context. One such example is the loss
of TACE activity, which renders cells highly sensitive to TNFα-
induced cell death (Pietri et al., 2013). The “loss of function”
hypothesis accommodates well with the neuroprotective activity
ascribed to PrPc (Resenberger et al., 2011b). Notably, the loss of
FIGURE 2 | Schematic representation of the corruption of
PrPc-mediated signaling in prion-infected cells. PrPSc accumulation is
associated with the constitutive recruitment of various effectors of PrPc,
including the Fyn kinase, the MAP kinases ERK1/2 and the CREB
transcription factor. Prion-infected cells also exhibit recruitment of the
stress-associated kinases p38 and JNK, which mirrors oxidative stress
conditions. A downstream event in this cascade is the drastic reduction in
MMP-9 mRNAs and activity, which, in turn, causes an impairment in Aβ
clearance, leading to Aβ accumulation. Aβ oligomers would bind PrPc and
possibly PrPSc and further fuel the activation of this signaling cascade,
thereby sustaining a vicious circle.
PrPc protective function within an infected context may relate to
the inability of PrPSc to undergo proteolytic processing at posi-
tion 111/112 (McMahon, 2012), and thereby generate the N1
fragment, endowed with neuroprotective activity (Guillot-Sestier
and Checler, 2012). Most likely, prion-associated neuropatho-
genesis involves both gain and loss of function events, that may
altogether promote synaptic dysfunction, oxidative stress, loss of
neuronal homeostasis and ultimately neurodegeneration (Kovacs
and Budka, 2008).
PrPC TRANSDUCES Aβ TOXICITY
The ﬁrst demonstration that PrPc can bind Aβ came from the
Strittmatter group in 2009, via an unbiased screening for receptors
that could bind Aβ42 oligomers in the form of Aβ-derived dif-
fusible ligands (ADDLs; Lauren et al., 2009). Lauren et al. (2009)
mapped the interaction site to residues 92-110 in PrPc, i.e., the
extremity of the N1 fragment (Figure 1), and showed that PrPc
supports about 50% of Aβ binding, in line with the multiplic-
ity of Aβ receptors (Benilova and De Strooper, 2013). In that
study, the impairment of synaptic plasticity fostered by ADDL
was shown to be PrPc-dependent. While the involvement of
PrPc in Aβ-induced neurotoxicity was initially subject to con-
troversy (Balducci et al., 2010; Calella et al., 2010; Kessels et al.,
2010; Cisse et al., 2011), possibly as a result of distinct experimen-
tal paradigms, notably in the preparation of Aβ mixtures (Nicoll
et al., 2013), all groups agreed that PrPc has very good afﬁnity
for Aβ (within the nanomolar range). Over the past three years,
the contribution of PrPc as a relay of Aβ-dependent pathogenic
effects has been corroborated and reﬁned by several studies. For
instance, targeting PrPc using neutralizing antibodies was shown
to counteract the Aβ-mediated impairment in synaptic plasticity
(Barry et al., 2011; Freir et al., 2011; Kudo et al., 2012). Molec-
ular analyses have further revealed that Aβ oligomers crosslink
PrPc to induce synaptic damage (Bate and Williams, 2011). As
for PrPSc, Aβ-induced toxic signaling via PrPc requires its GPI-
anchor, as well as lipid raft integrity (Resenberger et al., 2011a;
Um et al., 2012; Rushworth et al., 2013). Besides, Aβ was shown
to enhance the clustering of PrPc at the cell surface of neuronal
cells (Caetano et al., 2011). Taken together, these studies argue
that Aβ oligomers amplify the duration or strength of PrPc sig-
naling. This scenario is also supported by several reports that
have emphasized the corruption of the PrPc-Fyn signaling cas-
cade by Aβ (Larson et al., 2012; Um et al., 2012, 2013). Um et al.
(2013) were able to relate the Aβ-dependent subversion of the
PrPc coupling to Fyn to overactivation of the mGluR5 or NMDA
receptor (Um et al., 2012), the latter observation being recapitu-
lated in various other studies (Resenberger et al., 2011a; You et al.,
2012). Taking a step further, Larson et al. (2012) demonstrated
that the PrPc-Fyn complex promotes tau hyperphosphorylation
in response to oligomeric Aβ, thus providing some molecular
explanation for the well-established role of Fyn as a mediator of
Aβ/tau-associated toxicity (Ittner and Gotz, 2011; Roberson et al.,
2011). Whether the recruitment of the PrPc-Fyn complex by Aβ
impacts on additional signaling effectors such as NADPH oxidase,
similarly to PrPSc (Pradines et al., 2013), deserves further investi-
gation. Finally, the recent demonstration that the binding of Aβ
to PrPc and the ensuing toxic events can be efﬁciently inhibited
Frontiers in Aging Neuroscience www.frontiersin.org February 2014 | Volume 6 | Article 25 | 3
Hernandez-Rapp et al. Prion infection impairs Aβ clearance
by the PrPc alternate ligand STI-1 is providing a tangible avenue
to disrupt the deleteriousAβ-PrPc interaction (Ostapchenko et al.,
2013).
MULTIFACETED CONTROL OF PrPC ON Aβ PRODUCTION AND
AVAILABILITY
Aβ is generated from APP through the amyloidogenic processing
pathway, which involves the beta-secretase BACE1 and occurs in
a mutually exclusive fashion with the non-amyloidogenic path-
way largely controlled by the alpha-secretase TACE (Checler and
Vincent, 2002). In 2007, the Hooper group reported that PrPc
decreases the amyloidogenic processing of APP, thereby decreas-
ing Aβ levels, a property that is lost in the context of prion
infection (Parkin et al., 2007). Grifﬁths et al. (2011) went on to
show that PrPc interacts with BACE1 and controls its subcel-
lular compartmentation. Of note, while this spatial control is
protective toward the cleavage of wild-type APP, it does not pre-
vent BACE1 from processing the Swedish mutant form of APP
(Grifﬁths et al., 2011). Adding yet another layer of complex-
ity to the picture, PrPc also regulates the activity of TACE, a
function that is deviated in an Alzheimer’s context and causes
an imbalance of APP cleavage toward the amyloidogenic path-
way (Pietri et al., 2013). PrPc also regulates the availability of
Aβ at several levels. For instance, PrPc could favor the accu-
mulation of Aβ in the brain by contributing to its transcytosis
across the blood brain barrier (Pﬂanzner et al., 2012). Finally,
in accordance with the binding of Aβ to various sites located
within the N-terminal region of PrPc (Chen et al., 2010; see
Figure 1) and with the physiological processing of PrPc at
position 111/112, the resulting PrPc-derived N1 fragment was
reported to trap Aβ and thereby exert a protective action against
Aβ-induced cell death (Beland et al., 2012; Guillot-Sestier et al.,
2012).
HIJACKING PrPC SIGNALING BY PATHOGENIC PRIONS
CAUSES IMPAIRED Aβ CLEARANCE
As mentioned above, we documented that the subversion of PrPc
signaling by PrPSc in prion-infected cells leads to decreased activ-
ity of the MMP-9 metalloprotease (Pradines et al., 2013; Figure 2).
MMP-9 exhibits alpha-secretase activity (Fragkouli et al., 2012)
and also features among theAβ degrading enzymes [(De Strooper,
2010) for review]. On this basis, we examined the potential out-
come of the prion-dependent reduction in MMP-9 activity on Aβ
metabolism. By assessing the production and elimination rates
of Aβ peptides in prion-infected 1C11 cells, we substantiated an
imbalance in the clearance of Aβ under prion infection, which
was canceled after knockdown of the Fyn kinase (Pradines et al.,
2013; Figure 2). We further observed a similarly impaired Aβ
clearance in uninfected cells upon inhibition of MMP-9, high-
lighting the involvement of MMP-9 in this process. In agreement,
we found increased levels of Aβ in the supernatants of prion-
infected 1C11 cells or MMP-9 inhibitor-treated non-infected cells.
Besides, we monitored an increase in the cerebrospinal ﬂuid (CSF)
levels of Aβ in mice treated with a MMP-9 inhibitor as well as
in mice inoculated with prion-infected 1C11 cells. Altogether,
these results delineate a reciprocal connection between PrP and
Aβ that may sustain a pathogenic loop. Indeed, by promoting
an accumulation of Aβ in the extracellular space, prion infection
would fuel the recruitment of Fyn and its downstream targets
through the interaction of Aβ with PrP, whether in its cellular
or aggregated form (Chen et al., 2010; Zou et al., 2011). Whether
the subversion of PrPc dependent signal transduction by Aβ in
Alzheimer’s disease also negatively impacts on MMP-9 activity
and thereby impinges on Aβ clearance remains to be investigated.
Should it be conﬁrmed, disrupting this vicious circle would appear
as a promising avenue to combat both prion and Alzheimer’s
neuropathogenesis.
CONCLUDING REMARKS
As outlined above, tremendous progress has been achieved in
our understanding of the Aβ-PrPc interplay in very recent years.
The bidirectional relationship between these two proteins in sig-
nal transduction cascades may account for some -once puzzling-
observations that deposits of Aβ and PrP may co-occur in patients
with mixed AD and CJD clinical manifestation (Muramoto et al.,
1992; Hainfellner et al., 1998; Debatin et al., 2008). Beyond the var-
ious PrPc-Aβ connections summarized above, the possibility that
the interaction between the two proteins may favor their aggre-
gation in a “cross-seeding” fashion is beginning to be explored
(Morales et al., 2010). Overall, the more we learn in the ﬁeld,
the more we appraise the complexity of the PrPc-Aβ relationship.
The latest advance has further extended the points of conver-
gence in the molecular pathogenic pathways at play in the two
diseases, including loss of TACE activity (Pietri et al., 2013) and
impairment of the unfolded protein response (Moreno et al., 2012;
Ma et al., 2013). Striking differences however remain between
the two disorders, most notably the infectious properties spe-
ciﬁc to prions (Jucker and Walker, 2013). The only partial overlap
between the two pathologies may originate from the extremely
diverse array of PrPc and Aβ species as well as their promiscuous
partners (Linden et al., 2008; Benilova et al., 2012). Notwith-
standing, the central role ascribed to PrPc in deﬁned Aβ-related
toxic pathways opens new avenues for therapeutic intervention
in AD.
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